Confronting the challenges of postmenopausal urogenital health

Aging Health

Volumn 6, Issue 5, 2010, Pages 611-626

  Farage, Miranda A ^a   Miller, Kenneth W ^a   Ledger, William ^b  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

antimuscarinic drugs; dehydroepiandrosterone; DHEA; erosive lichen planus; hormone therapy; intravaginal estrogen; lichen sclerosus; menopause; postmenopausal; testosterone; tibolone; urinary incontinence; urogenital infections; vaginal atrophy

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; AROMATASE INHIBITOR; CONJUGATED ESTROGEN; CORTICOSTEROID; ESTRADIOL; ESTROGEN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PRASTERONE; PREDNISONE; PROGESTERONE; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TOLTERODINE;

ACNE; ARTHRALGIA; BEHAVIOR MODIFICATION; BREAST CANCER; BREAST TENDERNESS; CLINICAL TRIAL; CONSTIPATION; DIAPER; DIET; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPAREUNIA; EVENING DOSAGE; EXERCISE; FEMALE SEXUAL DYSFUNCTION; FIRST PASS EFFECT; HIRSUTISM; HORMONAL THERAPY; HOT FLUSH; HUMAN; INCIDENCE; INFECTION SENSITIVITY; LIBIDO DISORDER; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LOW DRUG DOSE; MASTALGIA; ORGASM DISORDER; PAIN; PATIENT COMPLIANCE; PELVIC FLOOR MUSCLE TRAINING; PELVIC ORGAN PROLAPSE; POSTMENOPAUSE; REVIEW; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; SYSTEMIC DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; UTERUS BLEEDING; VAGINA ATROPHY; VAGINA PESSARY; VAGINAL DRYNESS; VULVOVAGINITIS; XEROSTOMIA;

EID: 78149379772     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.10.44     Document Type: Review

References (109)

1. The 2009 Statistical Abstract. National Data Book. USA statistics in brief. Population-Sex, Age. US Census Bureau (2009).
2. Pandit L, Ouslander JG: Postmenopausal vaginal atrophy and atrophic vaginitis. Am. J. Med. Sci. 314(4), 228-231 (1997).
3. Gold EB, Bromberger J, Crawford S et al.: Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am. J. Epidemiol. 153(9), 865-874 (2001).
4. Huffman JW: The diagnosis and treatment of gynecologic disorders in elderly patients. Compr. Ther. 9(7), 54-60 (1983).
5. Iosif CS, Batra S, Ek A, Astedt B: Estrogen receptors in the human female lower uninary tract. Am. J. Obstet. Gynecol. 141(7), 817-820 (1981).
6. Hodgins MB, Spike RC, Mackie RM, MacLean AB: An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br. J. Obstet. Gynaecol. 105(2), 216-222 (1998).
7. Chen GD, Oliver RH, Leung BS, Lin LY, Yeh J: Estrogen receptor a and b expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women. Fertil. Steril. 71(6), 1099-1102 (1999).
8. Bachmann GA, Nevadunsky NS: Diagnosis and treatment of atrophic vaginitis. Am. Fam. Physician 61(10), 3090-3096 (2000).
9. Farage M, Maibach H: Lifetime changes in the vulva and vagina. Arch. Gynecol. Obstet. 273(4), 195-202 (2006).
10. Caillouette JC, Sharp CF Jr, Zimmerman GJ, Roy S: Vaginal pH as a marker for bacterial pathogens and menopausal status. Am. J. Obstet. Gynecol. 176(6), 1270-1275; discussion 1275-1277 (1997).
11. Gorodeski GI: Effects of estrogen on proton secretion via the apical membrane in vaginal-ectocervical epithelial cells of postmenopausal women. Menopause 12(6), 679-684 (2005).
12. Gorodeski GI, Hopfer U, Liu CC, Margles E: Estrogen acidifies vaginal pH by up-regulation of proton secretion via the apical membrane of vaginal-ectocervical epithelial cells. Endocrinology 146(2), 816-824 (2005).
13. Greendale GA, Judd HL: The menopause: health implications and clinical management. J. Am. Geriatr. Soc. 41(4), 426-436 (1993).
14. Stenberg A, Heimer G, Ulmsten U, Cnattingius S: Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 24(1-2), 31-36 (1996).
15. van Geelen JM, van de Weijer PH, Arnolds HT: Urogenital symptoms and resulting discomfort in non-institutionalized Dutch women aged 50-75 years. Int. Urogynecol. J. Pelvic Floor Dysfunct. 11(1), 9-14 (2000).
16. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT: Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am. J. Obstet. Gynecol. 168(3 Pt 1), 772-780 (1993).
17. Brizzolara S, Killeen J, Severino R: Vaginal pH and parabasal cells in postmenopausal women. Obstet. Gynecol. 94(5 Pt 1), 700-703 (1999).
18. McEndree B: Clinical application of the vaginal maturation index. Nurse Pract. 24(9), 48, 51-52, 55-56 (1999).
19. Hess R, Austin RM, Dillon S, Chang CC, Ness RB: Vaginal maturation index self-sample collection in mid-life women: acceptability and correlation with physiciancollected samples. Menopause 15(4 Pt 1), 726-729 (2008).
20. North American Menopause Society: Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17(2), 242-255 (2010).
21. Rossouw JE, Anderson GL, Prentice RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
22. Chlebowski RT, Kuller LH, Prentice RL et al.: Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360(6), 573-587 (2009).
23. Rossouw JE, Prentice RL, Manson JE et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13), 1465-1477 (2007).
24. Heiss G, Wallace R, Anderson GL et al.: Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299(9), 1036-1045 (2008).
25. Ravdin PM, Cronin KA, Howlader N et al.: The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356(16), 1670-1674 (2007).
26. Suckling J, Lethaby A, Kennedy R: Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 4, CD001500 (2006).
27. Notelovitz M, Funk S, Nanavati N, Mazzeo M: Estradiol absorption from vaginal tablets in postmenopausal women. Obstet. Gynecol. 99(4), 556-562 (2002).
28. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W: Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet. Gynecol. 112(5), 1053-1060 (2008).
29. Labrie F, Archer D, Bouchard C et al.: Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 16(5), 907-922 (2009).
30. Labrie F, Archer D, Bouchard C et al.: Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16(5), 923-931 (2009).
31. Labrie F, Cusan L, Gomez JL et al.: Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J. Steroid Biochem. Mol. Biol. 111(3-5), 178-194 (2008).
32. Hartmann U, Philippsohn S, Heiser K, Ruffer-Hesse C: Low sexual desire in midlife and older women: personality factors, psychosocial development, present sexuality. Menopause 11(6 Pt 2), 726-740 (2004).
33. Kanaly KA, Berman JR: Sexual side effects of SSRI medications: potential treatment strategies for SSRI-induced female sexual dysfunction. Curr. Womens Health Rep. 2(6), 409-416 (2002).
34. Kennedy SH, Rizvi S: Sexual dysfunction, depression, and the impact of antidepressants. J. Clin. Psychopharmacol. 29(2), 157-164 (2009).
35. Mortimer JE: Managing the toxicities of the aromatase inhibitors. Curr. Opin Obstet. Gynecol. 22(1), 56-60 (2010).
36. Kao A, Binik YM, Kapuscinski A, Khalife S: Dyspareunia in postmenopausal women: a critical review. Pain Res. Manag. 13(3), 243-254 (2008).
37. Eriksen PS, Rasmussen H: Low-dose 17 β-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol. 44(2), 137-144 (1992).
38. Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I: A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am. J. Obstet. Gynecol. 171(3), 624-632 (1994).
39. Lose G, Englev E: Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 107(8), 1029-1034 (2000).
40. Farage MA, Miller KW, Ledger WJ: Determining the cause of vulvovaginal symptoms. Obstet. Gynecol. Surv. 63(7), 445-464 (2008).
41. Farage MA, Galask RP: Vulvar vestibulitis syndrome: a review. Eur. J. Obstet. Gynecol. Reprod. Biol. 123(1), 9-16 (2005).
42. Hilditch JR, Lewis J, Peter A et al.: A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 61(1-2), 107-121 (2008).
43. Kloosterboer HJ: Tibolone: a steroid with a tissue-specific mode of action. J. Steroid Biochem. Mol. Biol. 76(1-5), 231-238 (2001).
44. Kenemans P, Speroff L: Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 51(1), 21-28 (2005).
45. Cummings SR, Ettinger B, Delmas PD et al.: The effects of tibolone in older postmenopausal women. N. Engl. J. Med. 359(7), 697-708 (2008).
46. Hubayter Z, Simon JA: Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric 11(3), 181-191 (2008).
47. Schwenkhagen A, Studd J: Role of testosterone in the treatment of hypoactive sexual desire disorder. Maturitas 63(2), 152-159 (2009).
48. Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N: The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas 6(4), 351-358 (1984).
49. Davis SR, McCloud P, Strauss BJ, Burger H: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21(3), 227-236 (1995).
50. Sherwin BB, Gelfand MM: The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom. Med. 49(4), 397-409 (1987).
51. Somboonporn W, Davis S, Seif MW, Bell R: Testosterone for peri- and postmenopausal women. Cochrane Database Syst. Rev. 4, CD004509 (2005).
52. Braunstein GD, Sundwall DA, Katz M et al.: Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch. Intern. Med. 165(14), 1582-1589 (2005).
53. Buster JE, Kingsberg SA, Aguirre O et al.: Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol. 105(5 Pt 1), 944-952 (2005).
54. Davis SR, van der Mooren MJ, van Lunsen RH et al.: Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 13(3), 387-396 (2006).
55. Shifren JL, Braunstein GD, Simon JA et al.: Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343(10), 682-688 (2000).
56. Simon J, Braunstein G, Nachtigall L et al.: Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J. Clin. Endocrinol. Metab. 90(9), 5226-5233 (2005).
57. Shifren JL, Davis SR, Moreau M et al.: Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 13(5), 770-779 (2006).
58. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, Derogatis L: Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J. Sex Med. 4(4 Pt 1), 1001-1008 (2007).
59. Davis SR, Moreau M, Kroll R et al.: Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med. 359(19), 2005-2017 (2008).
60. Laughlin GA, Goodell V, Barrett-Connor E: Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J. Clin. Endocrinol. Metab. 95(2), 740-747 (2010).
61. van Staa TP, Sprafka JM: Study of adverse outcomes in women using testosterone therapy. Maturitas 62(1), 76-80 (2009).
62. Hurd Clarke L: Older women and sexuality: experiences in marital relationships across the life course. Can. J. Aging 25(2), 129-140 (2006).
63. Dougan S, Payne LJ, Brown AE, Evans BG, Gill ON: Past it? HIV and older people in England, Wales and Northern Ireland. Epidemiol. Infect. 132(6), 1151-1160 (2004).
64. Karlovsky M, Lebed B, Mydlo JH: Increasing incidence and importance of HIV/AIDS and gonorrhea among men aged >/= 50 years in the US in the era of erectile dysfunction therapy. Scand. J. Urol. Nephrol. 38(3), 247-252 (2004).
65. Vasconcelos C, Guimaraes JM, Lisboa C, Ramos AS: Sexually transmitted diseases in the elderly. Review of 28 cases. Eur. J. Dermatol. 10(7), 567 (2000).
66. Golmeier D, Ridgway GL, Oriel JD: Chlamydial vulvovaginitis in a postmenopausal woman. Lancet 2(8244), 476-477 (1981).
67. Barton SE, Thomas BJ, Taylor-Robinson D, Goldmeier D: Detection of Chlamydia trachomatis in the vaginal vault of women who have had hysterectomies. Br. Med. J. (Clin. Res. Ed.) 291(6490), 250 (1985).
68. Pabich WL, Fihn SD, Stamm WE, Scholes D, Boyko EJ, Gupta K: Prevalence and determinants of vaginal flora alterations in postmenopausal women. J. Infect. Dis. 188(7), 1054-1058 (2003).
69. Heinemann C, Reid G: Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Can. J. Microbiol. 51(9), 777-781 (2005).
70. Devillard E, Burton JP, Hammond JA, Lam D, Reid G: Novel insight into the vaginal microflora in postmenopausal women under hormone replacement therapy as analyzed by PCR-denaturing gradient gel electrophoresis. Eur. J. Obstet. Gynecol. Reprod. Biol. 117(1), 76-81 (2004).
71. Oliveria SA, Klein RA, Reed JI, Cirillo PA, Christos PJ, Walker AM: Estrogen replacement therapy and urinary tract infections in postmenopausal women aged 45-89. Menopause 5(1), 4-8 (1998).
72. Ouslander JG, Greendale GA, Uman G, Lee C, Paul W, Schnelle J: Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. J. Am. Geriatr. Soc. 49(6), 803-807 (2001).
73. Brown JS, Vittinghoff E, Kanaya AM, Agarwal SK, Hulley S, Foxman B: Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet. Gynecol. 98(6), 1045-1052 (2001).
74. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst. Rev. 2, CD005131 (2008).
75. Eriksen B: A randomized, open, parallelgroup study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am. J. Obstet. Gynecol. 180(5), 1072-1079 (1999).
76. Raz R, Stamm WE: A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 329(11), 753-756 (1993).
77. Cardozo L, Lose G, McClish D, Versi E, de Koning Gans H: A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. Int. Urogynecol. J. Pelvic Floor Dysfunct. 12(1), 15-20 (2001).
78. Jackson SL, Boyko EJ, Scholes D, Abraham L, Gupta K, Fihn SD: Predictors of urinary tract infection after menopause: a prospective study. Am. J. Med. 117(12), 903-911 (2004).
79. SOGC clinical practice guidelines: The detection and management of vaginal atrophy. Number 145, May 2004. Int. J. Gynaecol. Obstet. 88(2), 222-228 (2005).
80. Johnston SL, Farrell SA, Bouchard C et al.: The detection and management of vaginal atrophy. J. Obstet. Gynaecol. Can. 26(5), 503-515 (2004).
81. Sobel JD: Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am. J. Obstet. Gynecol. 171(5), 1215-1220 (1994).
82. Ramer MA, Altchek A, Deligdisch L, Phelps R, Montazem A, Buonocore PM: Lichen planus and the vulvovaginal-gingival syndrome. J. Periodontol. 74(9), 1385-1393 (2003).
83. Mallett VT: Female urinary incontinence: what the epidemiologic data tell us. Int. J. Fertil. Womens Med. 50(1), 12-17 (2005).
84. Anger JT, Saigal CS, Litwin MS: The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. J. Urol. 175(2), 601-604 (2006).
85. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S: A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of incontinence in the county of Nord-Trondelag. J. Clin. Epidemiol. 53(11), 1150-1157 (2000).
86. Offermans MP, Du Moulin MF, Hamers JP, Dassen T, Halfens RJ: Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. Neurourol. Urodyn. 28(4), 288-294 (2009).
87. Subak LL, Richter HE, Hunskaar S: Obesity and urinary incontinence: epidemiology and clinical research update. J. Urol. 182(Suppl. 6), S2-S7 (2009).
88. Choi H, Palmer MH, Park J: Meta-analysis of pelvic floor muscle training: randomized controlled trials in incontinent women. Nurs. Res. 56(4), 226-234 (2007).
89. Subak LL, Wing R, West DS et al.: Weight loss to treat urinary incontinence in overweight and obese women. N. Engl. J. Med. 360(5), 481-490 (2009).
90. Burgio KL, Richter HE, Clements RH, Redden DT, Goode PS: Changes in urinary and fecal incontinence symptoms with weight loss surgery in morbidly obese women. Obstet. Gynecol. 110(5), 1034-1040 (2007).
91. Kuruba R, Almahmeed T, Martinez F et al.: Bariatric surgery improves urinary incontinence in morbidly obese individuals. Surg. Obes. Relat. Dis. 3(6), 586-590; discussion 590-581 (2007).
92. Aye C, Price N, Jackson SR: Urinary incontinence: can weight loss treat urinary incontinence in obese women? Nat. Rev. Urol. 6(5), 247-248 (2009).
93. Malone-Lee JG, Walsh JB, Maugourd MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. J. Am. Geriatr. Soc. 49(6), 700-705 (2001).
94. Alcalay M, Monga A, Stanton SL: Burch colposuspension: a 10-20 year follow up. Br. J. Obstet. Gynaecol. 102(9), 740-745 (1995).
95. Kjolhede P, Ryden G: Prognostic factors and long-term results of the Burch colposuspension. A retrospective study. Acta. Obstet. Gynecol. Scand. 73(8), 642-647 (1994).
96. Serels S: Thoughts on midurethral synthetic slings. Curr. Urol. Rep. 8(5), 359-363 (2007).
97. Bekker M, Beck J, Putter H et al.: Sexual function improvement following surgery for stress incontinence: the relevance of coital incontinence. J. Sex Med. 6(11), 3208-3213 (2009).
98. Brazzelli M, Murray A, Fraser C: Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J. Urol. 175(3 Pt 1), 835-841 (2006).
99. Hendrix SL, Cochrane BB, Nygaard IE et al.: Effects of estrogen with and without progestin on urinary incontinence. JAMA 293(8), 935-948 (2005).
100. Goldstein SR, Johnson S, Watts NB, Ciaccia AV, Elmerick D, Muram D: Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause 12(2), 160-164 (2005).
101. Quinn SD, Domoney C: The effects of hormones on urinary incontinence in postmenopausal women. Climacteric 12(2), 106-113 (2009).
102. Gomes CM, Arap S, Trigo-Rocha FE: Voiding dysfunction and urodynamic abnormalities in elderly patients. Rev. Hosp. Clin. Fac. Med. Sao Paulo 59(4), 206-215 (2004).
103. Hu TW, Igou JF, Kaltreider DL et al.: A clinical trial of a behavioral therapy to reduce urinary incontinence in nursing homes. Outcome and implications. JAMA 261(18), 2656-2662 (1989).
104. Fink HA, Taylor BC, Tacklind JW, Rutks IR, Wilt TJ: Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials. Mayo Clin. Proc. 83(12), 1332-1343 (2008).
105. Burgio KL, Locher JL, Goode PS et al.: Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 280(23), 1995-2000 (1998).
106. Koch LH: Help-seeking behaviors of women with urinary incontinence: an integrative literature review. J. Midwifery Womens Health 51(6), e39-e44 (2006).
107. Brown JS, Bradley CS, Subak LL et al.: The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann. Intern. Med. 144(10), 715-723 (2006).
108. Wilson L, Brown JS, Shin GP, Luc KO, Subak LL: Annual direct cost of urinary incontinence. Obstet. Gynecol. 98(3), 398-406 (2001).
109. Borrie MJ, Davidson HA: Incontinence in institutions: costs and contributing factors. CMAJ 147(3), 322-328 (1992).